Soft Tissue Sarcoma Market Research Report-Forecast till 2027

Soft Tissue Sarcoma Market Research Report – By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy), By Disease Type (Local, Regional, Metastatic Sarcoma), By Distribution Channel, By End User-Forecast till 2027

ID: MRFR/Pharma/3862-HCR | February 2021 | Region: Global | 90 pages

Soft Tissue Sarcoma Market Scenario


Soft tissue sarcoma is a type of cancer that develops from tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. Generally occuring in the muscles, tissues, and blood vessels that protect, support and surround the organs. Moreover, it is not categorized as tumor, but can be life-threatening if the cancer spreads to other parts of the body. There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others.

Currently, there are very few products approved for the treatment of soft tissue sarcoma. For instance, in October 2016, U.S. Food and Drug Administration issued an accelerated approval notice for Eli Lilly and Company’s drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types soft tissue carcinoma. Some of the drugs used for the treatment of soft tissue sarcoma include trabectedin (yondelis), sunitinib (sutent), sirolimus (rapamune), and doxorubicin (adriamycin), bevacizumab (avastin), and others.

Increase in the incidence and prevalence of different types of cancers, rising cases of soft tissue sarcoma, increasing R&D activities on drugs and other therapies, patent expiry of branded drugs, are some of the factors fuelling the growth of the soft tissue sarcoma market over the forecast period. However, stringent regulatory guidelines, adverse side effects of the treatment, and high cost for the radiotherapy and chemotherapy may hinder the growth of soft tissue sarcoma treatment market over the forecast period.

The methods for diagnosis of soft tissue sarcoma include some physical examination such as X-ray imaging, CT scan, MRI, ultrasound, PET scan and a biopsy. Such examinations in conjugation with other tests are important to plan a suitable treatment method for this condition.

The Global Soft Tissue Sarcoma Market is expected to grow at a CAGR of approximately 8.2% during the forecast period 2017-2023.

Soft Tissue Sarcoma Market Segmentation

The soft tissue sarcoma market is segmented on the basis of treatment, disease type, distribution channel, and end-users.

On the basis of the treatment type, the soft tissue sarcoma treatment market is segmented into targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy. Furthermore, the radiation therapy is subcatergorized into internal radiation therapy and external radiation therapy.

On the basis of the disease type, soft tissue sarcoma treatment market is segmented into local sarcoma, regional sarcoma, and metastatic sarcoma

On the basis of the distribution channel, soft tissue sarcoma treatment market is segmented into hospital pharmacies, retail pharmacies and others.

On the basis of the end user, the global soft tissue sarcoma treatment market has been segmented into hospitals, oncology centers, and long term care centers.

Soft Tissue Sarcoma Market- Key Players

Some of key the players in the global soft tissue sarcoma market are GlaxoSmithKline plc (U.K), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) and others.

Various key players are active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. GSK’s Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.

Research Methodology Soft Tissue Sarcoma Market Sources: Annual reports, Press release, White paper, and Company presentation

Soft Tissue Sarcoma Market Regional Analysis

The global soft tissue sarcoma market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.

The Americas soft tissue sarcoma market is projected to hold the largest share of the global soft tissue sarcoma market. Moreover, North America dominated the overall market in terms of revenue in 2016. According to American Cancer Society, approximately 12,390 people in 2016 were believed to suffer from  soft tissue sarcoma and related cancer. High incidence rate of soft tissue sarcomas, increase in awareness about this condition, rise in focus on healthcare, and well-established healthcare infrastructure are some of the factors driving the market in North America.

Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. The European soft tissue sarcoma market is expected to have a tremendous growth during the forecast period.

The market in Asia Pacific is estimated to expand at a high CAGR during the forecast period, led by an increase in government spending on healthcare services in India and China. The Middle East & Africa is projected to expand during the forecast period, owing to the rise in investments by market players and increase in prevalence of soft tissue sarcomas.

Intended Audience


  • Soft Tissue Sarcoma Drug Suppliers

  • Soft Tissue Sarcoma Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2017-2023: 8.2%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, distribution channel, and end-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline plc (U.K), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) and others
  Key Market Opportunities   Research and Development
  Key Market Drivers

  • High incidence rate of soft tissue sarcomas
  • Increase in awareness about soft tissue sarcoma market
  • Rise in focus on healthcare


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The outlook of the global soft tissue sarcoma market looks extremely promising.

    The global soft tissue sarcoma market is projected to grow at approximately 8.2% CAGR during forecast period (2017-2023).

    North America holds the largest share in the global soft tissue sarcoma market followed by Europe and Asia Pacific, respectively.

    Eli Lilly and Company (US), GlaxoSmithKline plc. (UK), Pfizer, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bristol-Myers Squibb (US), Johnson & Johnson Services, Inc. (US), Celgene Corporation (US), and Teva Pharmaceutical Industries Ltd (Israel), are some of the major players operating in the soft tissue sarcoma market.

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Treatment Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Soft Tissue Sarcoma Market, by Treatment

    6.1 Introduction

    6.2 Targeted therapy

    6.2.1 Market Estimates & Forecast, 2020 – 2027

    6.3 Chemotherapy

    6.3.1 Market Estimates & Forecast, 2020 – 2027

    6.4 Anti-angiogenesis Drug

    6.4.1 Market Estimates & Forecast, 2020 – 2027

    6.5 Radiation therapy

    6.5.1 Market Estimates & Forecast, 2020 – 2027

    6.5.2 Internal radiation therapy

    6.5.2.1 Market Estimates & Forecast, 2020 – 2027

    6.5.3 External radiation therapy

    6.5.3.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 7. Global Soft Tissue Sarcoma Market, by Disease type

    7.1 Introduction

    7.2 Local sarcoma

    7.2.1 Market Estimates & Forecast, 2020 – 2027

    7.3 Regional sarcoma

    7.3.1 Market Estimates & Forecast, 2020 – 2027

    7.4 Metastatic sarcoma

    7.4.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 8. Global Soft tissue sarcoma Market, by Distribution channel

    8.1 Introduction

    8.2 Hospital pharmacies

    8.2.1 Market Estimates & Forecast, 2020 – 2027

    8.3 Retail pharmacy

    8.3.1 Market Estimates & Forecast, 2020 – 2027

    8.4 Others

    Chapter 9. Global Soft Tissue Sarcoma Market, by End User

    9.1 Introduction

    9.2 Hospitals

    9.2.1 Market Estimates & Forecast, 2020 – 2027

    9.3 Oncology centers

    9.3.1 Market Estimates & Forecast, 2020 – 2027

    9.4 Long Term Care Center

    9.4.1 Market Estimates & Forecast, 2020 – 2027

    Chapter. 10 Global Soft Tissue Sarcoma Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.1 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 U.K

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Rest of the Middle East & Africa

    Chapter 11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    Chapter 12 Company Profiles

    12.1 GlaxoSmithKline plc

    12.1.1 Company Overview

    12.1.2 Treatment Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 F. Hoffmann-La Roche Ltd

    12.2.1 Company Overview

    12.2.2 Treatment Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Pfizer Inc.

    12.3.1 Company Overview

    12.3.2 Treatment Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Eli Lilly and Company

    12.4.1 Company Overview

    12.4.2 Treatment/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Johnson & Johnson Services, Inc.

    12.5.1 Company Overview

    12.5.2 Treatment Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 Teva Pharmaceutical Industries Ltd

    12.6.1 Company Overview

    12.6.2 Treatment Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 Bristol-Myers Squibb Company

    12.7.1 Overview

    12.7.2 Treatment Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Celgene Corporation

    12.8.1 Company Overview

    12.8.2 Treatment/Business Segment Overview

    12.8.3 Financial Overview

    12.8.4 Key Development

    12.8.5 SWOT Analysis

    12.9 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Pharmaceutical industry

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Soft tissue sarcoma Industry Synopsis, 2020 – 2027

    Table 2 Soft tissue sarcoma Market Estimates and Forecast, 2020 – 2027, (USD Million)

    Table 3 Soft tissue sarcoma Market by Region, 2020 – 2027, (USD Million)

    Table 4 Soft tissue sarcoma Market by Treatment, 2020 – 2027, (USD Million)

    Table 5 Soft tissue sarcoma Market by Disease types, 2020 – 2027, (USD Million)

    Table 6 Soft tissue sarcoma Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 7 Soft tissue sarcoma Market by End Users, 2020 – 2027, (USD Million)

    Table 8 North America Soft tissue sarcoma Market by Treatment, 2020 – 2027, (USD Million)

    Table 9 North America Soft tissue sarcoma Market by Disease types, 2020 – 2027, (USD Million)

    Table 10 North America Soft tissue sarcoma Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 11 North America Soft tissue sarcoma Market by End User, 2020 – 2027, (USD Million)

    Table 12 US Soft tissue sarcoma Market by Treatment, 2020 – 2027, (USD Million)

    Table 13 US Soft tissue sarcoma Market by Disease types, 2020 – 2027, (USD Million)

    Table 14 US Soft tissue sarcoma Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 15 US Soft tissue sarcoma Market by End User, 2020 – 2027, (USD Million)

    Table 16 Canada Soft tissue sarcoma Market by Treatment, 2020 – 2027, (USD Million)

    Table 17 Canada Soft tissue sarcoma Market by Disease types, 2020 – 2027, (USD Million)

    Table 18 Canada Soft tissue sarcoma Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 19 Canada Soft tissue sarcoma Market by End User, 2020 – 2027, (USD Million)

    Table 20 South America Soft tissue sarcoma Market by Treatment, 2020 – 2027, (USD Million)

    Table 21 South America Soft tissue sarcoma Market by Disease types, 2020 – 2027, (USD Million)

    Table 22 South America Soft tissue sarcoma Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 23 South America Soft tissue sarcoma Market by End User, 2020 – 2027, (USD Million)

    Table 24 Europe Soft tissue sarcoma Market by Treatment, 2020 – 2027, (USD Million)

    Table 25 Europe Soft tissue sarcoma Market by Disease types, 2020 – 2027, (USD Million)

    Table 26 Europe Soft tissue sarcoma Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 27 Europe Soft tissue sarcoma Market by End User, 2020 – 2027, (USD Million)

    Table 28 Western Europe Soft tissue sarcoma Market by Treatment, 2020 – 2027, (USD Million)

    Table 29 Western Europe Soft tissue sarcoma Market by Disease types, 2020 – 2027, (USD Million)

    Table 30 Western Europe Soft tissue sarcoma Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 31 Western Europe Soft tissue sarcoma Market by End User, 2020 – 2027, (USD Million)

    Table 32 Eastern Europe Soft tissue sarcoma Market by Treatment, 2020 – 2027, (USD Million)

    Table 33 Eastern Europe Soft tissue sarcoma Market by Disease types, 2020 – 2027, (USD Million)

    Table 34 Eastern Europe Soft tissue sarcoma Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 35 Eastern Europe Soft tissue sarcoma Market by End User, 2020 – 2027, (USD Million)

    Table 36 Asia Pacific Soft tissue sarcoma Market by Treatment, 2020 – 2027, (USD Million)

    Table 37 Asia Pacific Soft tissue sarcoma Market by Disease types, 2020 – 2027, (USD Million)

    Table 38 Asia Pacific Soft tissue sarcoma Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 39 Asia Pacific Soft tissue sarcoma Market by End User, 2020 – 2027, (USD Million)

    Table 40 The Middle East & Africa Soft tissue sarcoma Market by Treatment, 2020 – 2027, (USD Million)

    Table 41 The Middle East & Africa Soft tissue sarcoma Market by Disease types, 2020 – 2027, (USD Million)

    Table 42 The Middle East & Africa Soft tissue sarcoma Market by Distribution Channel, 2020 – 2027, (USD Million)

    Table 43 The Middle East & Africa Soft tissue sarcoma Market by End User, 2020 – 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Soft tissue sarcoma Market

    Figure 3 Segmentation Market Dynamics for Soft tissue sarcoma Market

    Figure 4 Global Soft tissue sarcoma Market Share, by Treatment 2020

    Figure 5 Global Soft tissue sarcoma Market Share, by Disease types 2020

    Figure 6 Global Soft tissue sarcoma Market Share, by Distribution Channel, 2020

    Figure 7 Global Soft tissue sarcoma Market Share, by End Users, 2020

    Figure 9 Global Soft tissue sarcoma Market Share, by Region, 2020

    Figure 10 North America Soft tissue sarcoma Market Share, by Country, 2020

    Figure 11 Europe Soft tissue sarcoma Market Share, by Country, 2020

    Figure 12 Asia Pacific Soft tissue sarcoma Market Share, by Country, 2020

    Figure 13 The Middle East & Africa Soft tissue sarcoma Market Share, by Country, 2020

    Figure 14 Global Soft tissue sarcoma Market: Company Share Analysis, 2020 (%)

    Figure 15 GlaxoSmithKline plc: Key Financials

    Figure 16 GlaxoSmithKline plc: Segmental Revenue

    Figure 17 GlaxoSmithKline plc: Geographical Revenue

    Figure 18 F. Hoffmann-La Roche Ltd: Key Financials

    Figure 19 F. Hoffmann-La Roche Ltd: Segmental Revenue

    Figure 20 F. Hoffmann-La Roche Ltd: Geographical Revenue

    Figure 21 Pfizer Inc.: Key Financials

    Figure 22 Pfizer Inc.: Segmental Revenue

    Figure 23 Pfizer Inc.: Geographical Revenue

    Figure 24 Eli Lilly and Company: Key Financials

    Figure 25 Eli Lilly and Company: Segmental Revenue

    Figure 26 Eli Lilly and Company: Geographical Revenue

    Figure 27 Johnson & Johnson Services, Inc..: Key Financials

    Figure 28 Johnson & Johnson Services, Inc..: Segmental Revenue

    Figure 29 Johnson & Johnson Services, Inc..: Geographical Revenue

    Figure 30 Teva Pharmaceutical Industries Ltd: Key Financials

    Figure 31 Teva Pharmaceutical Industries Ltd: Segmental Revenue

    Figure 32 Teva Pharmaceutical Industries Ltd: Geographical Revenue

    Figure 33 Bristol-Myers Squibb Company: Key Financials

    Figure 34 Bristol-Myers Squibb Company: Segmental Revenue

    Figure 35 Bristol-Myers Squibb Company: Geographical Revenue

    Figure 36 Celgene Corporation: Key Financials

    Figure 37 Celgene Corporation: Segmental Revenue

    Figure 39 Celgene Corporation: Geographical Revenue